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ABSTRACT 
 
With antigenically novel epidemic and pandemic influenza strains persistently on the horizon it is of 
fundamental importance that we understand whether heterosubtypic antibodies gained from exposures to 
circulating human influenzas exist and can protect against emerging novel strains. Our studies of IVIG 
obtained from an infection-naive population (Australian) enabled us to reveal heterosubtypic influenza 
antibodies that cross react with H5N1. We now expand those findings for an Australian donor population to 
include IVIG formulations from a variety of northern hemisphere populations. Examination of IVIGs from 
European and South East-Asian (Malaysian) blood donor populations further reveal heterosubtypic 
antibodies to H5N1 in humans from different global regions. Importantly these protect against highly 
pathogenic avian H5N1 infection in vitro, albeit at low titres of inhibition. Although there were qualitative 
and quantitative differences in binding and protection between globally different formulations, the 
heterosubtypic antibody activities for the respective IVIGs were in general quite similar. Of particular note 
because of the relative geographic proximity to the epicentre of H5N1 and the majority of human infections, 
was the similarity in the antibody binding responses between IVIGs from the Malayan peninsula, Europe and 
Australia. These findings highlight the value of employing IVIGs for the study of herd immunity, and 
particularly heterosubtypic antibody responses to viral antigens such as those conserved between circulating 
human influenzas and emerging influenza strains such as H5N1. They also open a window into a somewhat 
ill defined arena of antibody immunity, namely heterosubtypic immunity. 
 
KEYWORDS: Heterosubtypic, antibody, IVIG, influenza, H5N1, H1N1, H3N2  
© The Authors | Journal of Molecular and Genetic Medicine | December 2009 | Vol 3, No 2 | 217-224 | OPEN ACCESS 
218
INTRODUCTION 
 
Intravenous immunoglobulins (IVIGs) are widely used as 
highly-efficacious therapies to treat a broad range of 
conditions (Simon and Spath, 2003). Because IVIGs are 
highly-purified IgG products prepared from the plasmas of 
tens of thousands of blood donors they effectively reflect 
the herd immunity of their respective adult blood donor 
populations, and a sampling of the spectrum of antibodies 
to common infectious agents, such as influenza viruses. 
We earlier investigated whether Australian blood donors – 
uniquely geographically separated from the rest of the 
world on an island continent and naive to H5N1 exposure 
– may contain heterosubtypic antibodies, which cross-
react with H5N1. Indeed, we provided evidence for 
heterosubtypic antibodies that bound to many of the 
proteins of H5N1, including both surface as well as 
internal proteins (Lynch et al, 2008).        
 
There are considerable uncertainties that surround the 
current expansion of circulating H1N1, H5N1 and H9N2 
strains and their potential to evolve and re-assort to feed 
highly-pathogenic strains capable of human-to-human 
pandemic transmission. Consequently, the issue of 
whether there is a level of heterosubtypic antibody 
protection in the community at large to protect against 
newly emergent influenzas is of considerable importance. 
In this study we assessed whether intravenous 
immunoglobulins (IVIGs) from a range of different 
regions across the globe contain heterosubtypic antibodies 
reactive to avian H5N1 influenza. Utilizing IVIGs as a 
gauge of the herd IgG immunity of adult populations we 
determined whether there are heterosubtypic antibodies to 
H5N1 in IVIGs prepared from European and South East 
Asian (Malaysian) blood donors as we have found with 
Australian-derived IVIG. 
 
This study was designed to; i) assess the herd antibody 
immunity to a novel influenza, such as H5N1, ii) compare 
the herd immunities between geographically separate 
populations, and following positive affirmation, iii) profile 
the proteins of avian H5N1 influenza that IVIG cross-
reactive antibodies bind to, and of most importance, iv) 
determine whether heterosubtypic IVIG antibodies from 
different regions are capable of protecting against in vitro 
H5N1 infection. 
 
MATERIALS AND METHODS 
 
IVIGs 
The IVIGs studied were from a variety of different 
preparations, obtained from suppliers listed in Table 1. 
These highly-purified IgG preparations (≥ 96% pure) were 
isolated from plasma pools of up to 60,000 normal blood 
donors from the indicated geographical communities. 
IVIGs dilutions were prepared with TBS or PBS as 
indicated in the text. 
 
Influenza viruses 
A list of influenza viruses is provided in Table 2. The 
human viruses for this study were representative vaccine 
strains of previously circulating viruses, and were included 
in northern and southern hemisphere influenza vaccines 
between 1992 and 2000. These had been expanded in 
chicken eggs, and included two purified H1N1 and two 
H3N2 influenza isolates from humans obtained from the 
WHO laboratory, Parkville, Victoria, Australia. The avian 
influenza viruses examined included three H5N1 isolates, 
and for comparison H7N7 and H9N2 isolates. The avian 
viruses were grown in the allantoic sac of embryonated 
chicken eggs and purified in sucrose gradients. Briefly, 
allantoic fluid was collected from infected eggs, pooled 
and clarified by low speed centrifugation (10,000xg for 
10min). Virus was pelleted in an ultracentrifuge (80,000xg 
for 60min), resuspended in 5 ml TNE buffer (0.01 M Tris, 
0.001M EDTA, 0.1M NaCl, pH 7.2)  and purified by 
ultracentrifugation through a 20-50% discontinuous 
sucrose density gradient (80,000xg for 3hrs). The visible 
band of virus was extracted, and virus pelleted in an 
ultracentrifuge (80,000xg for 60min) and re-suspended in 
TNE buffer to 1% of the original volume of allantoic fluid. 
The A/Texas/36/1991 strain was represented in northern 
hemiphere vaccines (NHV) from 1992 to 1995, and for 
southern hemisphere vaccines (SHV) for 1997: the 
A/Beijing/32/1992 NHV 1993 to 1994; and the 
A/Sydney/5/1997 NHV 1997 to 2000 and SHV for 1998 to 
2000. 
 
The growth and expansion of the HPAI avian viruses was 
performed   at   the   CSIRO   Australian   Animal   Health 
Laboratories (AAHL), Geelong, Victoria. To permit removal 
from  the  AAHL  secure area and to allow the virus to be 
 
 
Table 1: Intravenous immunoglobulin (IVIG) preparations 
 
RegFormulation name  Prepared by  Donor plasma 
Intragam P-Aust  CSL  Australian 
Intragam P-Malay  CSL  Malaysian 
Sandoglobulin-Eur ZLBBioplasma  European 
Octagam-Eur Octapharma  European 
Carrimune-US CSLBehring  United  States 
Gamunex-US Talecris  United  States 
Octagam-US Octapharma  United  States 
 
 
 
Table 2: Influenza strains 
 
Label  Strain  Subtype  GeneBank#  Country 
α  A/Texas/36/1991 H1N1 ABF21312 United 
States 
β 
A/Johannesburg/ 
82/1996  H1N1 CY033610 South 
Africa 
γ  A/Beijing/32/1992 H3N2  GQ46319  China 
δ  A/Sydney/5/1997 H3N2 AB271703  Australia 
ζ 
A/Chicken/ 
Vietnam/8/’04  H5N1-1 AY724788 Vietnam 
θ 
A/Chicken/ 
Victoria/1985  H7N7 CY025069  Australia 
ι 
A/Duck/Malacca/ 
2003  H9N2 DQ139321  Malaysia  
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handled safely for antibody binding and protein analyses 
the viruses were inactivated by exposure to 5 megarads of 
radiation. The purity of the viruses was accessed by their 
SDS-PAGE profiles (see below and Lynch et al, 2008). 
 
Infection studies 
All experiments utilizing live HPAI viruses were 
performed in the high-security laboratories at AAHL. 
Virus neutralization assays were done in MDCK (Madin-
Darby Canine Kidney – ATCC CCL-34) cells or Vero 
(African green monkey kidney – ATCC CCL-81) using a 
modification of a standard protocol (Cottey et al, 2001). 
For this, 100 tissue culture infectious doses of each virus 
were added to two-fold dilutions of each serum or IVIG 
preparation in microtitre plate wells and incubated for 
60min at 37°C. Cells were added and the plates incubated 
at 37°C for 3 days. Viral activation by trypsin was 
unnecessary as all the viruses used in this study have a 
multi-basic cleavage site in their hemagglutinin protein. 
The neutralizing titre of serum or IVIG was the highest 
dilution giving complete neutralization of the virus. 
 
Two-dimensional (2D) gel electrophoresis 
Proteins were separated using 11cm precast immobilized 
pH gradients (IPG) across pH ranges 4-7 (Biorad, Life 
Sciences, Hercules, Ca, USA) and 6-11 (GE Healthcare, 
Uppsala, Sweden). 300μg of protein was loaded for each 
sample. Isoelectric focusing of proteins was conducted 
according to published techniques, in the pH range 4-7 
(Nouwens et al, 2000) and proteins were focused for a 
total of 35kVh. Proteins spanning pH 6-11 were cup 
loaded and focused as previously described (Nouwens et 
al, 2000) for a total of 38kvh. The IPG strips were 
reduced, alkylated, and the detergent was exchanged, prior 
to second dimension separation by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Nouwens et al, 2000). SDS-PAGE was carried out in 
11cm 8-16% (w/v) polyacrylamide/Tris-HCl gels (Bio-
Rad) using a Criterion Dodeca Cell (Bio-Rad). Gels were 
fixed in 10% (v/v) methanol, 7% (v/v) acetic acid for 1hr, 
and then stained with Sypro Ruby (Molecular Probes, OR, 
USA) overnight. Gels were de-stained for 2hr in 10% (v/v) 
methanol and 7% (v/v) acetic acid and scanned using a 
ProXPRESS Proteomic Imaging System (PerkinElmer, 
MA, USA).  
 
One-dimensional SDS-PAGE and immunoblotting 
Viruses were subjected to SDS-solubilization and 
electrophoretic separation in criterion (Biorad, Life 
Sciences, Hercules, CA, USA) 4-16% (w/v) gradient gels 
(SDS-PAGE) under non-reducing conditions (Sloane et al, 
2005). The relative molecular weights of influenza 
proteins were calculated from in-gel migration of pre-
stained molecular weight standards (Sea Blue Plus2; 
Invitrogen Life Sciences). As the mobility of some pre-
stained proteins can vary between batches as well as gel 
type, to account for this each batch used was compared in-
house against a panel of unstained proteins over the 
molecular weight range, and where necessary the assigned 
molecular weight were recalibrated for our tests. As 
indicated the SDS-PAGE gel separated viral proteins were 
visualised by Coomassie Blue R (Sigma-Aldrich) or silver 
staining (Biorad). 
For immunoblotting the SDS-PAGE separated viral 
proteins were electrotransfered onto 0.2µm Protran
reg 
nitrocellulose (Schleicher and Schuell, Whatman, PE- Life 
& Analytical Sciences, Boston, MA), followed by 
blocking with 5% (w/v) skimmed milk powder in TBS. 
The antibody-binding step was performed using 1/200-
1/500 dilutions of IVIG (50mg/ml), incubated for 1hr at 
room temperature (RT). After washing with TBS, blots 
were incubated at RT for 1hr with a 1/40,000 dilution of a 
horseradish peroxidase (HRP) goat anti-whole human 
antibody (Sigma-Aldrich chemicals, Mo). Following the 
removal of unbound secondary antibody by washing the 
immunoreactive bands were identified by chemi-
luminescence detection (HRP detection kit, Amersham 
Biosciences UK Ltd. Buckinghamshire, England) (Sloane 
et al, 2005). 
 
Antibody Binding Assays (MAP) 
To assess antibodies binding to a variety of common 
viruses, including human influenza viruses, globally 
different IVIG products were subjected to bead-based 
multianalyte profiling (MAP) at Rules-Based Medicine 
(www.rulesbasedmedicine.com) (Austin, Texas, USA), as 
described in detail by Bertenshaw and colleagues 
(Bertenshaw et al, 2008). The Influenza antigens used for 
the MAP analyses were from sonicates of purified Influenza 
A H3N2 strains A/Texas/1/1977 and A/Shandong/9/1993; 
and Influenza B, B/Hong Kong/5/1972. 
 
Viral microarray 
For binding of IVIG antibodies to influenza antigens, 
whole influenza antigen was robotically spotted in a 
protein array, and detected by influenza-specific 
antibodies in IVIG. Serial dilutions of influenza strains 
A/Sydney/5/1997 (H3N2) and A/Johannesburg/82/1996 
(H1N1), Tetanus toxoid, and BSA, were spotted 
(10nl/spot) onto nitrocellulose coated glass slides 
(Schleicher & Schuell, Dassel, Germany) using a 
Piezorray robotic arrayer (Perkin Elmer). Slides were 
cured overnight at 4ºC then blocked with 5% (w/v) 
skimmed milk in PBS. One slide without milk blocking 
was stained with Ponceau Red to visualise total protein. 
Reactivity to the spotted antigen was determined by 
incubating blocked slides with IVIG (1mg/ml in 
PBS/0.05%, w/v, Tween-20) for 2hr, followed by 2hr with 
anti-hIgG-HRP (1:2000 in PBS/Tween-20), and visualized 
with a peroxidase substrate kit (Becton Dickinson) 
according to the manufacturer’s instructions. 
 
RESULTS 
 
Antibodies in IVIGs to human and avian H5N1 
influenzas  
IVIGs are highly-purified IgG preparations prepared from 
large pools of human plasma and the immunoglobulin 
subtypes in IVIG formulations (i.e., IgG1, IgG2, etc) 
reflect those of normal plasma. The highly-purified nature 
of IVIGs is shown in Figure 1 of a protein stained 2D-gel 
electrophoresis map, and revealed heavy and light chains 
of these natural antibody  preparations  and  their  broad pI 
properties. In antibody binding studies using multiplex 
(Rules Based Medicine) and microarray binding assays 
(Figure 2A and B), there were quantitative and qualitative  
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Figure 1. 2D gel electrophoretic profile of a representative IVIG 
preparation, with IPG isoelectric fractionation over 4-7 pI range. 
The separation of protein molecular weight standard markers in 
the acrylamide separation phase is shown on the left hand side of 
the 2D-separated immunoglobulin fractions. Note, the respective 
IVIG formulations used in this study (Table 1) have been de-
identified, but each assigned a label A-G. The formulation used 
for 2D analysis was product D. 
 
 
differences in anti-influenza antibody binding to the 
antigens of H3N2 influenza A/Shandong/9/93, both 
between different IVIG preparations (data not shown), and 
within batches of a single IVIG preparation. Along with 
quantitative differences in antibody binding of 
immobilized, H1N1 and H3N2 strains of human influenza 
(Figure 2B). The relative binding of human antibodies in 
IVIGs was compared by the multianalyte profiling of 
antibodies to antigens of a variety of other viruses that 
commonly infect humans, namely herpes simplex virus 
(HSV), human papilloma virus (HPV), Influenza B (Infl 
B), respiratory syncytial virus (RSV) and Varicella Zoster 
(V. Zoster). As might be predicted the antibody responses 
against the highly antigenic herpes simplex and influenza 
A viruses that commonly infect humans predominate over 
quantitative responses to the other viruses examined.    
 
Comparison of IVIG antibody binding to H5N1 and 
human influenzas 
For comparison with our studies of H5N1 influenza 
proteins separated by SDS-PAGE, shown in Figure 3 are 
the protein bandings of the most prominent proteins of 3 
human influenza strains. Included are their relative 
molecular weights and understood per virion abundance 
(Privalsky and Penhoet, 1978; Lamb and Krug, 2001; 
Lynch et al, 2008). Between the protein profiles of the 
H1N1 and H3N2 strains, the stand out feature is the faster 
migrating HA (and oligomer) bands of H1N1 compared 
with H3N2 virus, reflecting glycosylation differences 
(namely, H3 > H1) (Lynch et al, 2008). For our studies we 
have equalized viral loading onto SDS-PAGE gels on the 
basis of protein equivalence, using the most abundant and 
detectable protein of influenza, M1, as an internal standard 
(Lynch et al, 2008). By immunoblotting using IVIGs from 
geographically quite separate populations from Europe 
(i.e., Sandoglobulin, Octagam), Australia (i.e., Intragam-P) 
and Malaysia (i.e., Intragam-Pm), that were isolated prior 
to December 2005 (i.e., in the period June 2004 to 
November 2005)  we  demonstrated that as for our earlier 
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Figure 2. Anti-human influenza binding antibodies in IVIGs: 
Assays for detection of Ab binding to conformational/ 
discontinuous influenza epitopes. A. Multiplex assay for anti-
influenza IVIG Ab binding showing a comparison of the 
antibody binding activities of 4 different batches of a single 
IVIG formulation. IVIG antibody binding to Influenza A: 
H3N2 A/Shandong/9/1993 and Influenza B: B/Hong 
Kong/5/1972 antigens displayed on microbeads and performed 
at the Rules Based Medicine biomarker testing laboratory 
using multianalyte bead Fluorescence 
(www.rulesbasedmedicine.com). Binding to herpes simplex 
virus (HSV), human pappilloma virus (HPV), Influenza B (Infl 
B) respiratory syncytial virus (RSV) and varicella zoster (V. 
Zoster) are also included for comparison. The Y-axis values 
show the amount of IVIG antibody that binds to the respective 
antigens coated on beads and expressed as the mean ratio of 
total antibody binding to the respective viral antigens 
compared to highly-validated RBM internal-reference control 
standards. B. Microarray slides spotted with viral dilutions (1-
0.125mg/ml) of H3N2 (A/Sydney/5/1997), H1N1 
(A/Johannesburg/82/1996), tetanus toxoid (Tet Tox) or BSA. 
IVIG-antibody (D-3) bind robotically arrayed whole 
inactivated influenza and tetanus toxoid. The BSA is negative. 
Spots are 10nl and 0.8mm apart. [Note: antigens were bound 
in duplicate arrays with (top array panel of each slide) and 
without (bottom array panel on each slide) 0.005% CHAPS. 
CHAPS was tested as a means of improving liquid flow rates 
in the Piezorray, but as shown, had no influence on protein 
binding to the array substrate.]  
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Virion Protein (kDa)
X (30-60) PB2 87
X (30-80) PB1 86.5
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X 1,000 NP 56-60
X 100 NA 58
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Figure 3. SDS-PAGE gel separations of influenza proteins 
showing coomassie-stained protein signatures of purified 
preparations of the human H1N1 A/Johannesbeg/82/1996 (β), and 
H3N2 strains A/Beijing/ 32/1992 (γ) and A/Sydney/5/97 (δ). The 
viruses used have been assigned a greek letters (Table  2). Relative 
molecular weights (Privalsky and Penhoet, 1978; Lynch et al, 
2008) and approximate copies per virion (Lamb and Krug, 2001) 
for each of the influenza proteins are listed in the left panel. 
 
 
studies of human antibodies in Australian IVIG, that similar 
binding activities for avian H5N1 influenza proteins are 
widely found in all of the different IVIG preparations 
(Figure 4). IVIG antibodies from the various products 
bound equivalently to the highly conserved M1 protein 
across H5N1, H1N1 and H3N2 influenza virusus. From 
these immunoblotting comparisons we find equivalent IVIG 
antibody binding to the abundant and conserved internal M1 
and NP proteins between H5N1, H1N1 and H3N2 isolates. 
With minimal binding to the far more heterogeneous HA 
and NA envelope proteins of H5N1 compared to the human 
isolates, for which the latter show marked binding activities 
to the surface and immunodominant HA proteins (including 
oligomeric forms) of each of the human strains (Figure 4). 
When matched side-by-side differences in binding profiles 
for the human influenza isolates between the IVIG 
preparations undoubtedly reflects differences in the 
environmental strain-specific exposure and vaccination 
between the respective donor communities. As reported 
earlier (Lynch et al, 2008) and here, low levels of antibodies 
that bind to the HA of H5N1 are revealed by long exposure 
times. The specificity and heterosubtypic properties of this 
H5N1 antibody binding activity in IVIG and normal human 
serum was demonstrated by various means, including 
selective depletion by adsorption to human H3N2 and 
H1N1 influenza proteins in the absence of quantitative non-
specific depletion of the total IVIG pool of IgGs (Lynch et 
al, 2008; Stelzer-Braid et al, 2008; and unpublished data). 
 
Heterosubtypic human antibodies to avian influenza 
Optimization of chemiluminescence exposure times for 
avian H5N1 immunoblots has enabled more finite detection 
of human antibodies in IVIGs to many of the proteins of 
H5N1 (Lynch et al, 2008). This is further demonstrated in 
Figure 5, where several different avian isolates were 
examined by SDS-PAGE immunoblotting and compared 
directly with human H1N1 influenza at a 1/10 lower protein 
loading. As demonstrated in our earlier report, when 
optimized for signal detection human antibodies in globally 
different IVIG preparations revealed antibodies that bind 
with many of the H5N1 protein, none-the-least to H5 HA 
(Lynch et al, 2008). The faster migrating H5 HA on SDS-
PAGE is indicative of lower total carbohydrate 
compositions than for the HA of H1 or H3 of human 
influenza viruses. These observations were made from 
consistent findings for the  respective avian strains but we 
acknowledge a limited sampling and need for a more 
expansive examination of additional avian isolates. 
Consistent in our studies were apparent differences in the 
quantitative binding of antibodies in IVIGs for avian HAs 
with H9> H5> minimal if any H7 binding; and qualitative 
binding showing prominent apparent binding to the high 
molecular weight polymeric forms of H9 HA compared to 
H5 HA. More in-depth examination of avian strains is now 
needed to access and substantiate indicated differences in 
human IVIG antibody binding profiles between strains. 
 
Human antibodies in IVIG protect against H5N1 
infection in cell culture 
As indicated from the comparative immunoblotting 
profiling of IVIGs antibodies above the low levels of 
heterosubtypic human antibodies that bind to H5N1 HA is 
of the order of 100-1000 times less than antibody binding 
to human influenza (H3N2, H1N1) HAs. Strain-specific 
human serum antibodies routinely give high neutralization 
titres in,  in  vitro,  infection  assays  of  human  influenza 
infection. In contrast, any human antibody disruption of 
infection of a completely foreign influenza strain, such as 
H5N1, would likely be minimal, particularly considering 
the level of binding to H5N1 observed above. Despite this, 
when northern hemisphere IVIGs were tested in cell 
culture for H5N1 neutralization, we observed bona fide 
protection, albeit with modest titres with 100% inhibition 
(Table 3).  These activities were similar to the 
neutralization levels observed within the same experiments 
in assays of southern hemisphere, Australian-derived 
IVIG, as reported earlier (Lynch et al, 2008) and 
duplicated her for direct comparison. Each of the IVIG 
preparations inhibited infections of 3 strains of H5N1 (i.e., 
2 clade representative strains – one from human and two 
from avian infections), when tested in both Vero and 
MDCK cell culture infections. As each of the IVIG 
preparations inhibit the infections of 3 strains of H5N1 but 
not the infection of H7N7 virus, strain-specific 
heterosubtypic protection is implicated. The individual and 
combined roles of anti-HA and NA antibodies (as well as 
the more abundant antibodies to NP, M1, NS2) in 
providing this protection remain to be defined. 
 
DISCUSSION 
 
H5N1 continues to be a major global health concern, with 
60% mortality among humans and 100% among some bird 
species. Understanding the immune mechanisms that 
underpin the immune protection in human survivors is 
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Figure 4. IVIG mmunoblotting profiles of human H1N1, H3N2 and avian H5N1 influenza proteins that bind human antibodies. 
Purified influenza samples were applied to 5-15% (w/v) SDS-PAGE gels and immunoblotted with the European (Sando-globulin-
Eur, Octagam-Eur), Australian (Intragam P-Aust) or Malaysian (Intragam P-Malay) IVIGs. The Greek alphabets denote IVIG 
products, while the numbers A-2, B-1, C-1 and D-1 represent the particular batch of the product. The H5N1 virus (i.e., purified 
A/Chicken/Vietnam /8/2004 and identified as H5), is compared with the human H1N1 strains  A/Texas/36/1991 (α) and 
A/Johannesbeg /82/1996 (β), and the H3N2 strains A/Beijing/32/1992 (γ) and A/Sydney/5/97 (δ).  
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Table 3. IVIG neutralization of H5N1 infection of Vero and MDCK cells. IVIG products from Europe (Octagam-Europe) (2 
batches), Australia (Intragam P-Australia) and Malaysia (Intragam P-Malay) were examined in triplicate. These respective IVIG 
preparations are listed in this table using de-identified labels, A to D. [*Denotes duplicate experiments] 
 
IVIG 
HAPI influenza A virus strain – Vero cell infection 
Chick/viet/8/’04 
H5N1 (Vietnam) 
Chick/wates/1/’05 
H5N1 (Indonesia) 
Human/viet/1203/’04 
H5N1 (Vietnam) 
Chick/victoria/’85 
H7N7 (Australia) 
A  8-16* 32  32* <2* 
B  <2 & 2*  8  2-8*  <2* 
C  2-4* 8  8-16*  <2* 
D  8* 64  8-32*  <2* 
  MDCK cell infections 
A  8 1024  128  ND 
B  4 1024  32 ND 
C  16 512 32 ND 
D  16 512  256  ND 
Figure 5. Identification of heterosubtypic 
IVIG antibody binding to the proteins of 
avian viruses by immunoblotting. IVIG 
antibody binding H5N1 protein signatures 
have been observed for Intragam P-Aust, 
Sandoglobulin-Eur, and Octagam-Eur 
IVIGs, or Intragam P-Malay. Two different 
IVIG formulations reactive to the proteins of 
H5N1 (A/Chicken/ Vietnam/8/2004), H7N7 
(A/Chicken/Victoria/1985) and H9N2 
(A/Duck/Mellacca /2003) avian strains are 
shown, and for comparison a human H1N1 
(A/Johannesburg/82/1996) is shown at a 
1/10 protein loading compared to the avian 
viruses.  
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therefore of fundamental importance, in order to firstly 
understand natural protection against any future expansion 
of H5N1 or other emerging new influenzas (e.g., the 2009 
H1N1), and secondly to harness any heterosubtypic 
immune protection through the design of new vaccines and 
antivirals. Undoubtedly, innate and heterosubtypic cellular 
immune mechanisms protect against infection or disease 
of novel influenza viruses, but these are unlikely to explain 
the observed 40% level of ‘natural’ protection against 
H5N1 human infections. We believe our findings of 
heterosubtypic anti-H5N1 reactive antibodies in different 
unexposed populations offer an insight into a tenable 
process of adaptive antibody immunity to protect against 
novel influenzas such as H5N1. Following on from our 
earlier reports (Lynch et al, 2008; Stelzer-Braid et al, 
2008), where we identified anti-H5N1 directed human 
antibodies in sera and IVIG preparations from Australian 
blood donors we now show that IVIGs from different 
geographic populations from the northern hemisphere, and 
notably from European blood donations collected prior to 
the emergence of avian H5N1 influenza in Europe, 
similarly share this property. This suggests that some pre-
existing heterosubtypic ‘herd’ antibody immunity to avian 
H5N1 influenza may be a universal characteristic of 
populations across the globe. To demarcate a 
heterosubtypic response from the well-studied ‘seasonal’ 
adaptive response that current vaccines stimulate we refer 
to this particular type of humoral immunity as a ‘seasoned’ 
adaptive response.  
 
While the value of strain-specific antibodies to protect 
against seasonal influenzas is well appreciated and 
understood, any suggestion of broad acting antibodies to 
protect against hitherto unseen novel influenza viruses (e.g., 
from birds or pigs) has till now been overlooked. From our 
observations we propose that pre-existing heterosubtypic 
antibodies in the community may offer a molecular 
mechanism to explain protection against H5N1 and past 
pandemic strains, and together with innate and 
heterosubtypic cellular immune protection could provide a 
significant barrier of protection for novel viruses. Our 
findings here and in previous reports give direct evidence 
that heterosubtypic ‘seasoned’ antibody responses to novel 
influenza viruses do exist, but what we do not yet know are 
the sites and mechanisms involved, and most importantly, in 
the wider context the significance of this response for 
natural protection against emerging infections and whether 
it could be harnessed for new styled anti-virals. 
 
This proposition gives rise to a number of predictions, 
which themselves can be examined and challenged, and if 
found to be of value, appropriately validated. These relate 
to the influenza protein epitopes that heterosubtypic 
antibodies target, and how an adaptive heterosubtypic 
humoral response may be established and progressed. We 
predict the development of antibodies to sites that are 
highly-conserved across influenza viruses, such that, when 
a new and antigenically novel influenza virus arises 
antibodies to exposed conserved sites, irrespective of the 
strain, could bind and disrupt viral infection and growth. 
In support of this concept the extent of binding of 
heterosubtypic antibodies of human serum and IVIGs to 
influenza target proteins directly correlates with the extent 
of the viral protein cross-strain sequence conservation. In 
making this comparison we benefit from the bioinformatic 
assessments of Bui et al (2007) and Heiny et al (2008) of 
conserved sites across a wide variety of influenza strains. 
Particularly significant is the study by Heiny and 
colleagues involving examination of 36,343 influenza A 
sequences of linear stretches of 9 amino acids or more that 
were conserved across influenza subtypes (Heiny et al, 
2007). On those criteria, they identified a wide range of 
conserved sequences between the different proteins. 
Notably, they found that 50% of the protein sequence of 
polymerase protein PB2 is widely conserved followed by 
36% conservation of PB1, 27% of M1, 25% of NP, 16% of 
PA, and only 2% of HA. On this basis, none of the 
proteins NA, PB1-F2, M2, NS1 or NS2 had fully 
conserved regions across this large sequence data base 
(Heiny et al, 2007). Within the sensitivity constraints of 
our studies and restricted to the most abundant proteins 
(see Figure 3) we broadly found that antibody binding was 
preferential for the H5N1 proteins with the highest 
sequence conservations with human influenzas (Figure 5). 
One notable example was that of the most abundant 
influenza protein, the matrix protein M1 of H5N1 with 
27% conserved stretches of sequence, which we found to 
have equivalent IVIG antibody binding as for the M1 
protein of human H1N1 and H3N2 influenza strains (also 
see Lynch et al, 2008). These considerations do not 
however take into account the contributions of other 
heterosubtypic antibody responses to conserved, linear 
regions of less than 9 amino acids, or to conserved 
discontinuous epitopes. Unequivocal validation of each of 
the antibody-epitope interactions is now required to define 
the respective antibody binding kinetics and saturation, 
and by peptide and protease fragmentation studies coupled 
with mass spectrometry to definitively resolve the target-
epitopes and match against conserved sites predicted from 
bioinformatics data-base screening and molecular 
modelling. 
 
In this study we used IVIGs as a tool to broadly study 
human antibodies for H5N1. However, IVIGs as a 
potential therapeutic option in the event of the sudden 
emergence of a HPI pandemic could also be considered. 
IVIGs are well-tolerated therapies for primary and 
secondary immune-deficiencies and autoimmune disorders 
(Simon and Spath, 2003). However, while IVIGs and 
hyper-immune immunoglobulins are highly valued and 
studied therapies for a variety of infectious agents, 
including CMV and hepatitis viruses (Gupta et al, 1996), 
there is a notable paucity of information in the literature on 
the anti-viral properties of IVIGs for common viral agents, 
such as for influenzas. If it was possible to identify a 
cohort of individuals with solid pre-existing seasoned 
immunity for hyper-immune heterosubtypic anti-influenza 
antibodies for passive immune therapy, this could add an 
additional therapeutic asset to complement small molecule 
anti-virals and vaccines. If hyper-immune anti-influenza 
IVIG were possible, in addition to harvesting pandemic 
convalescent influenza antibodies they would offer an 
already licensed production-capable fallback therapy 
option during a HPI pandemic. The passive transfer of 
antibodies for the protection of infection-naïve individuals 
at risk from pandemic influenza was successfully deployed  
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in 1918 and more recently in the successful treatment of an 
individual infected with H5N1, and to this day 
convalescent ‘Spanish Flu’ survivors have retained 
protective antibody responses to the 1918 H1N1 influenza 
(Luke et al, 2006). The antibody repertoires of 
convalescent individuals would be particularly beneficial, 
as they would possess a complement of both seasoned and 
seasonal antibodies to protect against epidemic and 
pandemic influenzas. Furthermore, as there is growing 
evidence implicating the prominent role of secondary 
infections in the mortality of pandemic influenzas, IVIGs, 
as broad anti-infective agents, may also be beneficial in a 
pandemic as a backup for antibiotics, to keep secondary 
infections in check (e.g., bacterial pneumonia, CMV, 
tuberculosis) (Klugman et al, 2009a; Klugman et al, 
2009b) and to suppress overt host cytokine-storm 
responses particularly in younger individuals, who are 
prime targets for pandemic influenza mortality.  
 
As the quest in the design of universal vaccines and 
inhibitors for influenza gains momentum we may well 
learn many essential lessons from how heterosubtypic 
antibody immunity has developed in nature to protect 
against new infectious challenges. 
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LIST OF ABBREVIATIONS 
 
Ab: Antibody 
CHAPS: 3-[(3-Cholamindopropyl)dimethylamminio-1-
propanesulfate 
HPI: High-pathogenic influenza 
HPV: Human papilloma virus 
HRP: Horseradish peroxidase 
HSV: Herpes simplex virus 
IgG: Immunoglobulin G 
IVIG: Intravenous immunoglobulins 
KDa: Kilodalton 
MAP: Multianalyte profiling 
MDCK: Madin-Darby canine kidney 
MW: Molecular weight 
PBS: Phosphate-buffered saline 
RSV: Respiratory syncytial virus 
RSV: Respiratory syncytial virus 
TBS: Tris-buffered saline 
TNE: Tris/NaCl/EDTA buffer 
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